儿童用布地奈德效果好吗

On October 3, 2001, it was announced that the company's capsules containing budesonide had been approved by the FDA. Budesonide is a glucocorticoid with potent local anti-inflammatory effects. It can enhance the stability of endothelial cells, smooth muscle cells and lysosomal membranes, inhibit immune responses and reduce antibody synthesis, thereby reducing the release and activity of allergic active mediators such as histamine. It can also reduce the enzymatic process triggered when antigens and antibodies are combined, inhibit the synthesis and release of bronchoconstrictive substances and reduce the contractile response of smooth muscles.

Clinical trials have shown that Budesonide (Budenofalk) has good efficacy and high safety when used in bronchial asthma. The trial selected 85 patients with bronchial asthma who received treatment and divided them into an experimental group of 43 patients and a control group of 42 patients using the random number table method. Patients in the control group were treated with albuterol sulfate, and patients in the experimental group were treated with Budesonide (Budenofalk). After 2 weeks, the treatment effects and incidence of adverse reactions were compared. Results: The treatment effectiveness rate of patients in the experimental group was 95.35%, which was significantly higher than the 69.05% in the control group, and the difference was statistically significant. No patients in the two groups experienced serious adverse reactions. The incidence of adverse reactions in the experimental group was significantly lower than that in the control group, and the difference was statistically significant.

Childhood asthma is a lung disease that often presents with difficulty breathing, which can be very distressing for the child. Budesonide is indicated for patients with glucocorticoid-dependent or -independent bronchial asthma and asthmatic chronic bronchitis. Is budesonide effective for children?

Compared with budesonide and oral glucocorticoids, inhaled glucocorticoids have lower systemic effects when reaching equivalent anti-asthmatic doses; children under 2 years old should be used with caution or not. Therefore, the use of budesonide in pediatric patients requires the above consent to avoid inappropriate use of the drug that may harm health.